Open AccessInhibition of Growth and Metastasis of Tumor in Nude Mice after Intraperitoneal Injection of Bevacizumab
Author(s) -
Zhao Zexue,
Li Xiang,
Liu Weidong,
Liu Xiaozhou,
Wu Sujia,
Hu Xiaohui
Publication year - 2016
Publication title -
orthopaedic surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.666
H-Index - 23
eISSN - 1757-7861
pISSN - 1757-7853
DOI - 10.1111/os.12236
Subject(s) - bevacizumab , intraperitoneal injection , metastasis , medicine , angiogenesis , osteosarcoma , saline , vascular endothelial growth factor , urology , pathology , nuclear medicine , andrology , chemotherapy , cancer , vegf receptors
Objective To explore the inhibitory effect of bevacizumab, a vascular endothelial growth factor antibody, on angiogenesis in human osteosarcoma of nude mice. Methods Twenty‐one nude mice were inoculated with red fluorescent protein ( RFP )‐labeled human osteosarcoma cell line 143 B‐RFP, that is, clones that expressed RFP in the cytoplasm, and randomly assigned to one of three groups: G1 ( C ontrol group, injected with saline solution); G 2 (intraperitoneal bevacizumab 2 mg/kg twice per week) and G 3 (intraperitoneal bevacizumab 5 mg/kg, twice per week). The tumor‐bearing mice were examined in a fluorescence light box that was illuminated periodically. The primary tumors were measured by fluorescence imaging weekly and their volumes calculated. Results The mean tumor volumes were significantly smaller in the G 3 (186.4 ± 100.8 mm 3 ) than the control group (587.0 ± 406.8 mm 3 ) ( P < 0.05) on Day 31, and again significantly smaller in the G 3 (677.3 ± 461.9 mm 3 ) than the control group (3162.6 ± 1529.2 mm 3 ) on Day 38 ( P < 0.01). The average tumor volume in the G 2 group was 493.5 ± 425.4 mm 3 on Day 31 and 1870.1 ± 1524.8 mm 3 on Day 38. The effect on tumor volume was greater in the G 3 than the G 2 group. Three mice in the G 2 group, four in the G 3 group and four in the control group developed lung metastases that were confirmed by pathological examination; these differences were not statistically significant ( P < 0.05). Conclusions Bevacizumab exhibits strong antiangiogenesis activity in experimental osteosarcoma in a nude mouse model but does not influence the incidence of lung metastasis. Our findings may have considerable potential for the treatment of osteosarcoma.